Roche and BSBE signed Reagent Purchase Agreement to supplement the coagulation test menu

Beijing Strong Biotechnologies, Inc. (BSBE. 300406) announced on the evening of September 21 that the company signed reagent purchase agreement with Roche Diagnostics (Shanghai) Co., Ltd.

The announcement stated that Roche Diagnostics purchased kits suitable for Roche Diagnostics' automatic coagulation analyzers from BSBE to supplement its coagulation detection menu. The product distribution period is from October 1, 2021 to September 30, 2027.

The cooperation between BSBE and Roche Diagnostics has further expanded their respective market shares in the field of coagulation analysis and diagnosis, and has a positive and significant significance for the development of both enterprises. This cooperation also shows that BSBE’s blood coagulation diagnostic products have been recognized by well-known international companies in terms of R&D, production and quality control.